Two Nature stakes! Chinese scientists isolate SARS-CoV-2-specific neutralizing antibodies from patients!

June 3, 2020 /
BiovalleyBIOON / -- A global outbreak of 2019 coronavirus disease (COVID-19) caused by SARS-CoV-2 is a global health emergency, requiring the urgent need for therapeutic drugs and preventive vaccines to alleviate the outbreakAntibodies are one of the effective drugs to treat COVID-19, there are manyclinical trialsare using the recovery of the patient's serum treatment, but this method is difficult to mass production, while the number of antibodies in the patient's serum is numerous, the specificity is uncertain, so the effect is unknownSo finding SARS-CoV-2-specific neutral antibodies from these recovered patients is critical to the development and mass production of therapeutic antibodies in the next stepOn May 26, Nature magazine published two new studies by Chinese scientists that isolated HIGHly active neutralizing antibodies specific to SARS-CoV-2 from patientsone of the studies, entitled "A human neutrality antibody targets the body of the body of the body of SARS-CoV-2", was completed by the Yan Jinghua team of the Institute of Microbiology of the Chinese Academy of Sciences, the Gaofu team, Wang Qihui team in collaboration with the Wuhan Virus Institute of the Chinese Academy of Sciences, the Institute of Viral Diseases of the National Center for Disease Control and Prevention, beijing Ditan Hospital and other institutionsIn the study, the researchers reported the separation of two specific human monoclonal antibodies (MAbs): CA1 and CB6 from a patient with a recovery period OF COVID-19image source: Natureresearchers found that CA1 and CB6 exhibited strong SARS-CoV-2-specific middleand activity in vitroIn addition, CB6 can inhibit SARS-CoV-2 infection in rhesus monkeys in preventive and therapeutic environmentsFurther structural studies show that CB6 can identify epitopes that overlap with the angiotensin-converting enzyme 2 (ACE2) in the SARS-CoV-2 receptor binding domain (RBD), thus interfering with the interaction of viruses/receptors through spatial bit resistance and direct interface-residual competitive actionThese results suggest that CB6 is worth further clinical studies and transformationanother study entitled "Human neutralization antibodies by SARS-CoV-2 infection" was carried out by zhang Linyi team of Tsinghua University School of Medicine and Zhang Zheng team of the National Center for Clinical Medical Research on Infectious Diseases, and Wang Xinquan, Director of the School of Life Sciences of Tsinghua University and The High Precision Innovation Center for Structural Biology SARS-CoV-2 into the target cell relies on the binding of the receptor binding domain (RBD) of the viral protoprotein and the binding between the ACE2 cell receptor In this study, the researchers reported isolating and identifying 206 RBD-specific monoclonal antibodies from a single B cell in eight cases of SARS-CoV-2 infection The researchers identified antibodies that are effectively anti-SARS-CoV-2 neutralizing, which are associated with the competitiveness of ACE2 in combination with RBD picture Source: Nature Surprisingly, despite the discovery of a large number of plasma cross-reactions against its triaphosproprotein, neither the anti-SARS-CoV-2 antibodies nor the infected plasma has cross-reacted with SARS-CoV or MERS-CoV RBDs The crystal structure analysis of RBD binding antibodies shows that spatial level resistance inhibits the binding of the virus to ACE2, thus blocking the entry of the virus These findings suggest that anti-RBD antibodies are viral-specific inhibitors The antibodies found here may be candidate antibodies for the development of SARS-CoV-2 clinical interventions in general, , both studies have found highly neutralized all-humanantibodies specific to SARS-CoV-2, laying a solid foundation for the development and optimization of the next step of SARS-CoV-2 therapeutic antibodies (biovalleybioon.com) References: Shi, R., Shan, C., Duan, X et al.
A human neutralizing antibody targets the receptor binding site of SARS-CoV-2.
Nature (2020) https://doi.org/10.1038/s41586-020-2381-y
Ju, B., Zhang, Q., Ge, J et al.
Human neutralizing antibodies elicited by SARS-CoV-2 infection.
Nature (2020) https://doi.org/10.1038/s41586-020-2380-z